Hepatitis Therapeutics Market – Global Industry Analysis and Forecast (2022-2029)

Hepatitis Therapeutics Market is expected to reach USD 19.05 billion by 2029, with a CAGR of 3.5 % between 2021 and 2029.

Hepatitis is described as liver inflammation. Hepatitis A, B, and C are the most prevalent types of hepatitis.

The research gives a comprehensive perspective of the market by combining qualitative and quantitative data. It examines the global Hepatitis Therapeutics Market and provides forecasts for the key segments. It also includes market size and forecast estimates for five key regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, for the years 2021 to 2027. The Hepatitis Therapeutics Market is further split into countries and markets within each location.

To know about the Research Methodology :- Request Free Sample Report

In the report, 2021 is considered a base year however 2021’s numbers are on the real output of the companies in the market. Special attention is given to 2021 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and a specific strategic analysis of those companies is done in the report.
Hepatitis Therapeutics Market Dynamics
Increased incidences of hepatitis infection are being caused by rising alcohol and drug usage, as well as large populations living in unsanitary settings. As a result of these reasons, the Hepatitis Therapeutics Market is expected to rise at an exponential rate. The increased awareness among various countries and global organizations about the necessity of hepatitis eradication would be a crucial driver in the growth of the Hepatitis Therapeutics Market. For example, the WHO issued a recommendation in 2021 for viral hepatitis eradication by 2030. Furthermore, many activities such as World Hepatitis Day assist government entities in spreading hepatitis awareness. These initiatives act as growth catalysts for the Hepatitis Therapeutics Market.

In addition, the rise in the prevalence of various hepatitis, expanding research and development work, clinical trials of hepatitis drugs, an increase in the number of item endorsements and product launches, and the development of novel hepatitis drugs in the treatment of various types of hepatitis are driving the growth of the Hepatitis Therapeutics Market. Increasing research collaboration for the development of potent drugs in the pipeline promotes considerable market growth. Furthermore, associations and collaborative efforts in important organizations are increasing persistent awareness in regards to hepatitis therapeutics treatment, and the presentation of low-cost hepatitis therapeutics are distinct variables that promote market growth.

In the Hepatitis Therapeutics Market, the Hepatitis C Segment is expected to hold a Major Market Share.

Hepatitis C symptoms can range from minor to life-threatening. Acute hepatitis C occurs within the first six months of hepatitis C virus contact, while chronic hepatitis C can lead to lifelong hepatitis C if not treated.

According to World Health Organization (WHO) figures published in July 2021, an estimated 58 million individuals have chronic hepatitis C virus, with around 1.5 million new infections occurring each year. According to the same source, the hepatitis C virus is a blood-borne disease, with exposure to tiny quantities of the blood being the most prevalent mode of infection.

In the Hepatitis Therapeutics Market, the hepatitis C sector holds a significant market share. It is expected to follow a similar trend in the forecast period, owing to the high incidence of hepatitis C in both emerging and developed countries, as well as the increasing market availability of effective medications.
Hepatitis Therapeutics Market Regional Insight
In 2021, the North American market accounted for 42.9 % of revenue, owing to strong demand in the United States, significantly higher patient affordability, and regional awareness of advanced treatments. Some of the critical elements leading to the high share include the availability of well-developed healthcare infrastructure, reimbursement, and access to the most innovative drugs.

Over the forecast period, the Asia Pacific market is expected to grow at the quickest pace of 5.8 percent. High disease burden, increasing access to medications, improvements in healthcare and sanitation, and increased awareness of hepatitis immunisation are likely to boost the region's growth prospects. Countries such as India, China, Indonesia, and other South Asian economies, for example, are continually expanding their healthcare expenditure.

Besides, the rising demand for generic medications is expected to benefit the Asia Pacific region. Gilead has licensed seven Indian producers to offer hepatitis medications to various regions of the world. More than half of the HCV-infected people live in the countries covered by this agreement. The Medicine Patent Pool's varied licences permit multiple manufacturers to develop generic versions of these HCV treatments even when the drugs are patented, which is projected to affect the market throughout the forecast period, by lowering drug prices and increasing consumption rate.

However, MEA and Latin America are expected to have considerable growth due to high prevalence rates and an increase in the import of generic drugs to treat various hepatitis disorders. As the patient population in the United States and other developed countries declines owing to the excellent outcomes of HCV medications, several manufacturers are expanding their operations in the MEA and Latin America regions to meet the significant unmet demands for improved treatment.

Report Objectives:

• Landscape analysis of the Hepatitis Therapeutics Market
• competitive benchmarking
• Past and current status of the industry with the forecasted market size and trends
• Evaluation of potential key players that include market leaders, followers, and new entrants
• Technology trends
• The potential impact of micro-economic factors on the market
• External and Internal factors affecting the market have been analyzed

The report also helps in understanding the Hepatitis Therapeutics Market dynamics, and structure by analysing the market segments to project the Hepatitis Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Hepatitis Therapeutics Market make the report investor’s guide.
Hepabtitis Therapeutics Market Scope: Inquire before buying



Hepatitis Therapeutics Market


Report Coverage
Details


Base Year:
2021
Forecast Period:
2022-2029


Historical Data:
2017 to 2021
Market Size in 2021:
US $ 14.47 Bn


Forecast Period 2022 to 2029 CAGR:
3.5 %
Market Size in 2029:
US $ 19.05 Bn.


 Segments Covered:
by Disease Type
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others


by Drug Class
• Oral antivirals
• Immune modulators


by Distribution Channel
• Hospital pharmacies
• Drug stores & retail pharmacies
• Online providers



Hepatitis Therapeutics Market by Region
• North America
• Europe
• Asia pacific
• The Middle East and Africa
• South America
Hepatitis Therapeutics Market: Key Players
• Abbvie Inc.
• Bristol Myers & Squibb
• Cipla Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc.
• Hoffmann-La Roche Ltd.
• Lupin Ltd.
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila.
• Hetero Healthcare Limited
• NATCO Pharma Limited

Frequently Asked Questions

1. What is the projected market size & growth rate of the Hepatitis Therapeutics Market?
Ans- The Hepatitis Therapeutics Market was valued at USD 14.47 billion in 2021 and is projected to reach USD 19.05 billion by 2029, growing at a CAGR of 3.5 % during the forecast period.

2. What are the key driving factors for the growth of the Hepatitis Therapeutics Market?
Ans- Increased incidences of hepatitis infection is being caused by rising alcohol and drug usage, as well as large populations living in unsanitary settings

3. Which Region accounted for the largest Hepatitis Therapeutics Market share?
Ans- In 2021, North America accounted for 42.9 % of the global Hepatitis Therapeutics Market.

4. What makes North America a Lucrative Market for Hepatitis Therapeutics Market?
Ans- Some of the critical elements leading to the high share include the availability of well-developed healthcare infrastructure, reimbursement, and access to the most innovative drugs.

5. What are the top players operating in the Hepatitis Therapeutics Market?
Ans- Abbvie Inc., Bristol Myers & Squibb, Cipla Inc., and Gilead Sciences Inc.